Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Tongji Hospital · Huazhong University of Science and Technology · +3 more institutions
Abstract
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs), has shaped therapeutic landscape of some type of cancers. Despite some ICIs have manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. Exploring additional immune checkpoint molecules is a hot research topic. Recent studies have identified several new immune checkpoint targets, like lymphocyte…
Citation impact
- FWCI
- 60.20
- Percentile
- 100%
- References
- 138
Authors
6- SQShuang QinCorresponding
Tongji Hospital, Huazhong University of Science and Technology
- LXLinping Xu
Zhengzhou University, Henan Cancer Hospital
- MYMing Yi
Tongji Hospital, Huazhong University of Science and Technology
- SYShengnan Yu
Tongji Hospital, Huazhong University of Science and Technology
- KWKongming Wu
Zhengzhou University, Henan Cancer Hospital, Tongji Hospital, Union Hospital, Huazhong University of Science and Technology
Topics & keywords
- Immune checkpoint
- TIGIT
- CTLA-4
- Immune system
- Biology
- Cytotoxic T cell
- Immunology
- Monoclonal antibody
- Good health and well-being